Jessica B. Langbaum
YOU?
Author Swipe
View article: Evaluation of self‐mediated alternatives for risk testing education and return of results (eSMARTER) study: A randomized study of methods for returning <i>APOE</i> and pTau‐217 results
Evaluation of self‐mediated alternatives for risk testing education and return of results (eSMARTER) study: A randomized study of methods for returning <i>APOE</i> and pTau‐217 results Open
INTRODUCTION Disclosing Alzheimer's disease (AD) genetic and biomarker information is becoming increasingly common but often resource‐intensive, requiring a clinician to return results. As results become relevant for clinical care and more…
View article: Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3 Open
INTRODUCTION TRAILBLAZER‐ALZ 3 is investigating donanemab in preclinical Alzheimer's disease (AD). METHODS This double‐blind, placebo‐controlled trial used a plasma phosphorylated tau‐217 (p‐tau217) assay to detect AD pathology for eligibi…
View article: What is older adults’ understanding of Alzheimer's disease research registries? Findings from 20 focus group studies
What is older adults’ understanding of Alzheimer's disease research registries? Findings from 20 focus group studies Open
INTRODUCTION Research registries address the challenges associated with enrollment of individuals in research studies by matching members to current studies and trials in need of participants. However, recruitment into research registries …
View article: Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment Open
View article: Study Design of the Evaluation of Self‐Mediated Alternatives for Risk Testing Education and Return of Results ‐ E‐SMARTER: A randomized trial from the Alzheimer’s Prevention Initiative program
Study Design of the Evaluation of Self‐Mediated Alternatives for Risk Testing Education and Return of Results ‐ E‐SMARTER: A randomized trial from the Alzheimer’s Prevention Initiative program Open
Background Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer’s disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return o…
View article: The new landscape of <i>APOE</i> genotyping in the Alzheimer’s Clinic: Harnessing genetic counseling experience to create digital tools to support patients considering anti‐amyloid therapies
The new landscape of <i>APOE</i> genotyping in the Alzheimer’s Clinic: Harnessing genetic counseling experience to create digital tools to support patients considering anti‐amyloid therapies Open
Background With the advent of FDA approved anti‐amyloid therapy and recognition of increased side effects in APOE e4 carriers, APOE testing is now recommended for patients considering anti‐amyloid therapies such as lecanemab. Given the the…
View article: Theory-Based Message Design for Recruitment of Underrepresented Racial/Ethnic Groups Into Alzheimer’s-Focused Research Registries
Theory-Based Message Design for Recruitment of Underrepresented Racial/Ethnic Groups Into Alzheimer’s-Focused Research Registries Open
Alzheimer’s disease (AD)-focused recruitment research registries can help identify eligible participants for AD studies, but registry participation is limited among racial and ethnic groups most at risk for AD. Using the Reasoned Action Ap…
View article: Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies
Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies Open
INTRODUCTION The Alzheimer's Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer's disease (AD) prevention. The studies were terminated early, and the reversibility of umibecestat's side ef…
View article: Intuition Brain Health Study: a smartphone- and smartwatch-based virtual, observational study using multimodal mobile sensing to classify and detect mild cognitive impairment
Intuition Brain Health Study: a smartphone- and smartwatch-based virtual, observational study using multimodal mobile sensing to classify and detect mild cognitive impairment Open
Smart devices are utilized by billions worldwide. The ubiquity of consumer-grade smart devices provides opportunities to robustly capture real-world cognition. Intuition (NCT05058950) was a virtual, observational study that enrolled 23,004…
View article: A chance to prevent Alzheimer's disease sooner than you think
A chance to prevent Alzheimer's disease sooner than you think Open
View article: Learning About a Heightened Genetic Risk for Dementia: Anticipated Stigma is Greater than Experienced Stigma
Learning About a Heightened Genetic Risk for Dementia: Anticipated Stigma is Greater than Experienced Stigma Open
View article: Knowledge of Risk Factors for Dementia and Attitudes on a Dementia Prevention Program by Age and Ethnicity in Arizona
Knowledge of Risk Factors for Dementia and Attitudes on a Dementia Prevention Program by Age and Ethnicity in Arizona Open
View article: Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired <i>APOE</i> ε4 homozygotes
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired <i>APOE</i> ε4 homozygotes Open
INTRODUCTION Alzheimer's Prevention Initiative Generation Study 1 evaluated amyloid beta (Aβ) active immunotherapy (vaccine) CAD106 and BACE‐1 inhibitor umibecestat in cognitively unimpaired 60‐ to 75‐year‐old participants at genetic risk …
View article: Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab Open
Background A number of extended families in Colombia with early‐onset ADAD have a PSEN1 mutation at codon 280 (E280A), comprise the largest ADAD kindred in the world. Trial participants have been treated with crenezumab (an experimental an…
View article: Impact of reference region on longitudinal florbetapir PET SUVR changes from the API ADAD Colombia Trial
Impact of reference region on longitudinal florbetapir PET SUVR changes from the API ADAD Colombia Trial Open
Background We previously examined the impact of using a cerebellar, pons, or cerebral white matter (WM) reference region (RR) on the ability of each to distinguish cortical measures of fibrillar amyloid‐(Aβ) deposition with baseline data i…
View article: Informed consent process experience in Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Colombia trial
Informed consent process experience in Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Colombia trial Open
Background Recruiting cognitively‐unimpaired volunteers at high genetic risk of developing dementia into the Alzheimer’s Prevention Initiative (API) Colombia trial, and maintaining study adherence for at least 5 years has been a monumental…
View article: Contraception in Female Volunteer in Alzheimer’s Prevention Initiative Autosomal‐dominant Alzheimer’s disease Colombia Trial, a Phase II Clinical Trial to Test Safety and Efficacy of Crenezumab
Contraception in Female Volunteer in Alzheimer’s Prevention Initiative Autosomal‐dominant Alzheimer’s disease Colombia Trial, a Phase II Clinical Trial to Test Safety and Efficacy of Crenezumab Open
Background In most prevention clinical trials contraceptive use is required. The API ADAD Colombia Trial was a phase II, double‐blind, placebo‐controlled clinical trial to evaluate the safety and efficacy of the investigational product cre…
View article: Spillover Effects of COVID-19 News Coverage on Willingness to Participate in Medical Research in a Diverse Sample of US Older Adults
Spillover Effects of COVID-19 News Coverage on Willingness to Participate in Medical Research in a Diverse Sample of US Older Adults Open
COVID-19 has dominated news coverage since the beginning of the pandemic. The extent to which exposure to such news affected perceptions of medical research and other health issues is not clear, especially among older adults who are more s…
View article: Psychological Status of the Participants in Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia
Psychological Status of the Participants in Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia Open
Background: The SARS-CoV2 global pandemic impacted participants in the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) clinical trial, who faced three stressors: 1) fear of developing dementia; 2) conc…
View article: Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies Open
View article: Understanding Barriers and Facilitators to Signing Up for a Mobile-Responsive Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies
Understanding Barriers and Facilitators to Signing Up for a Mobile-Responsive Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies Open
View article: How intention to join an Alzheimer's participant recruitment registry differs by race, ethnicity, sex, and family history: Results from a national survey of US adults
How intention to join an Alzheimer's participant recruitment registry differs by race, ethnicity, sex, and family history: Results from a national survey of US adults Open
INTRODUCTION Alzheimer's‐focused participant recruitment registries are tools for accelerating enrollment into studies, however, registry members are primarily White women. METHODS We conducted a national online survey of 1501 adults ages …
View article: Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease Open
View article: Tracking COVID-19 vaccination expectancies and vaccination refusal in the United States
Tracking COVID-19 vaccination expectancies and vaccination refusal in the United States Open
To identify factors that predict COVID-19 vaccination refusal and show how expectancies affect vaccination acceptance for non-vaccinated adults, we used a monthly repeated cross-sectional sample from June/2021 to October/2021 to collect da…
View article: A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial Open
Introduction The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti‐oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian prese…
View article: Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease Open
Background : There is a critical need for novel primary endpoints designed to detect early and subtle changes in cognition in clinical trials targeting the asymptomatic (preclinical) phase of Alzheimer’s disease (AD). The Alzheimer’s Preve…
View article: “I feel it in my gut:” Epistemic motivations, political beliefs, and misperceptions of COVID-19 and the 2020 U.S. presidential election
“I feel it in my gut:” Epistemic motivations, political beliefs, and misperceptions of COVID-19 and the 2020 U.S. presidential election Open
This project examines the intersection of political constructs and epistemic motivations as they relate to belief in misinformation. How we value the origins of knowledge – through feelings and intuition or evidence and data – has importan…
View article: Factors associated with COVID-19 masking behavior: an application of the Health Belief Model
Factors associated with COVID-19 masking behavior: an application of the Health Belief Model Open
Wearing a face mask is effective in minimizing the spread of coronavirus disease 2019 (COVID-19) among unvaccinated individuals and preventing severe illness among the vaccinated. Country, state and local guidelines promote, and at times m…
View article: Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease Open
A crucial aspect of any clinical trial is using the right outcome measure to assess treatment efficacy. Compared to the rapidly evolved understanding and measurement of pathophysiology in preclinical and early symptomatic stages of Alzheim…
View article: Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials Open
Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and retention of a large number of qualified…